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Invasive fusariosis is a highly aggressive fungal infection associated with high mortality in heavily immu-
nocompromised patients. Although posaconazole is efficacious as salvage therapy against infections caused by
Fusarium species, concerns remain regarding this agent in the setting of reduced potency. To evaluate the
efficacy of posaconazole as treatment or prophylaxis against invasive fusariosis caused by Fusarium solani, we
utilized a neutropenic murine model of disseminated disease. ICR mice were administered escalating doses of
posaconazole (6.25, 12.5, 25, or 50 mg/kg of body weight twice daily [BID]) by oral gavage beginning 2 days
prior to inoculation in the prophylaxis studies or beginning 12 h after inoculation as treatment. Therapy was
continued until day 9 postinoculation, and animals were monitored off therapy until day 15 for survival. Fungal
burden was assessed as CFU in the kidneys. A clear dose-response relationship was observed, as the highest
dose of posaconazole (50 mg/kg) was the most effective in prolonging survival and reducing tissue fungal
burden both as prophylaxis and as treatment. This dose response was associated with high posaconazole serum
concentrations as measured by bioassay. However, the extent of efficacy was also dependent on the infecting
inoculum, as greater increases in survival and reductions in fungal burden were observed with the lower
inocula tested. In this model high dosages of posaconazole were effective as treatment and prophylaxis against
disseminated fusariosis caused by F. solani.
Fusarium species are among the leading causes of invasive
mold infections among patients with hematologic malignancies
and those undergoing hematopoietic stem cell transplantation
(HSCT), with mortality exceeding 70% (1, 2, 15). Risk factors
for disseminated infection include neutropenia, lymphopenia,
graft-versus-host disease, corticosteroids, and immunosuppres-
sive therapy (1, 2). In vitro studies have reported moderate to
negligible activity of available antifungals against Fusarium,
with amphotericin B and itraconazole having minimal activity
(3, 8, 16). Reduced in vitro potency has also been reported for
voriconazole and posaconazole when measured by standard mi-
crodilution methodology (3, 8, 16). However, both voriconazole
and posaconazole have been shown to be effective in animal
models of invasive fusariosis, including infections caused by iso-
lates with reduced in vitro susceptibility (4, 10, 20).
Modifications to testing parameters used in determining the
in vitro activity (e.g., inoculum size and incubation period) may
greatly affect the MIC against Fusarium isolates (8, 16). This
suggests that the in vitro activity as measured by standard
microdilution methodology may not be predictive of in vivo
efficacy. Our objective was to assess the in vivo efficacy of
posaconazole against disseminated fusariosis caused by Fusar-
ium solani, both as treatment and as prophylaxis, and to com-
pare this activity to the in vitro potency measured at 24 and
48 h against different starting inocula. In addition, posacon-
azole concentrations were measured in animals that were ad-
ministered the same dosages used for treatment and prophy-
laxis.
MATERIALS AND METHODS
Isolate. F. solani species complex clinical isolate 95-2478 was obtained from
the University of Texas Health Science Center at San Antonio. Conidia were
inoculated onto potato dextrose agar and allowed to incubate at 37°C for 10 days.
A mixture of micro- and macroconidia were harvested by flooding the plates with
sterile physiologic saline and gentle scraping.
Antifungals. For in vitro testing, posaconazole (Schering-Plough, Kenilworth,
PA) was dissolved in dimethyl sulfoxide (DMSO), and further dilutions were
made in RPMI medium supplemented with 2% glucose and buffered with 0.165
M 4-morpholinepropanesulfone acid (pH 7.0). For in vivo studies, the commer-
cially available posaconazole oral suspension (Noxafil; Schering-Plough) was
used.
In vitro susceptibility and pharmacodynamics. The in vitro potency and phar-
macodynamics of posaconazole were measured using the CLSI M38-A broth
microdilution and the tetrazolium salt 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide (XTT) colorimetric assays, respectively (8, 11,
13). Briefly, conidia were added to microtiter trays containing posaconazole
(final concentration range, 0 to 8 g/ml) in RPMI with 2% glucose to achieve a
starting inoculum of either 1  104 or 1  105 conidia/ml. After 24 and 48 h of
incubation, the MIC was read as the lowest concentration of posaconazole that
resulted in complete visual inhibition of growth compared to the growth control.
The XTT assay was performed in triplicate as previously reported (12). Absor-
bance was read at 492 nm using a microplate spectrophotometer, and readings
were converted to percent absorbance (growth control wells set as 100%, me-
dium control wells set as 0%).
Bioassay. Serum concentrations of posaconazole were measured in uninfected
and nonimmunosuppressed mice following 5 doses of posaconazole at 6.25, 12.5,
25, or 50 mg/kg of body weight administered twice daily (BID) 4 h following
administration of the last dose. Posaconazole concentrations were measured by
bioassay using previously described methods (9, 19). Briefly, 100 l of serum was
instilled in duplicate into wells cored into potato dextrose agar that had been
inoculated with 1  104 cells/ml of Candida kefyr ATCC 66028. After 48 h of
incubation, zones of inhibition were measured, and posaconazole concentrations
were interpolated from a standard curve.
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Infection model. An established murine model of invasive fusariosis was used
for all experiments (4). Outbred ICR mice were rendered temporarily neutro-
penic by a single dose of 5-fluorouracil (150 mg/kg intravenously [i.v.]) 1 day
prior to inoculation. Mice were infected intravenously using an 0.2-ml volume of
inoculum. Different starting inocula were tested and ranged from 7.5  104 to
2.9 106 conidia/mouse. This protocol was approved by the Institutional Animal
Care and Use Committee at the University of Texas Health Science Center at
San Antonio, and animals were maintained in accordance with the standards of
the American Association for Accreditation of Laboratory Animal Care (14).
Prophylaxis and treatment. For treatment and prophylaxis studies four
posaconazole regimens (6.25, 12.5, 25, and 50 mg/kg administered by oral gavage
BID) were compared to untreated controls. In prophylaxis studies (n  10
animals per regimen within each regimen), posaconazole was begun 2 days prior
to inoculation, while in treatment studies (n  20 animals per regimen) therapy
began 12 h after inoculation. Animals that appeared moribund prior to the end
of the study were euthanized, the kidneys were harvested, and death was re-
corded as occurring the next day. Kidneys were homogenized in sterile saline by
using a tissue homogenizer, and serial dilutions were prepared in sterile saline
and plated onto potato dextrose agar. Following 48 h of incubation, the number
of CFU per gram of kidney tissue for each animal was calculated. Treatment
studies were repeated on separate occasions to ensure reproducibility.
Data analysis. The XTT reduction assay data were fitted to a four-parameter
inhibitory sigmoid model (modified Hill equation) using computer curve-fitting
software (Prism 5; GraphPad Software, Inc.) to derive concentrations resulting in
50% and 90% inhibition (IC50 and IC90, respectively). Goodness of fit was
assessed by R2 and standard error of the IC50 value. Survival was plotted by
Kaplan-Meier analysis, and differences in median survival time and percent
survival were analyzed by the log rank test and Fisher’s exact test, respectively.
Differences in fungal burden endpoints between control and each antifungal regi-
men were assessed for significance by the Mann-Whitney test. A P value of 0.05
was considered statistically significant.
RESULTS
In vitro susceptibility and pharmacodynamics. Similarly to
previous studies we found discordant in vitro susceptibility and
pharmacodynamic results for posaconazole between the two
incubation periods and starting inocula (16). At the lower
inoculum, a 4-fold increase in the MIC from 2 to 8 g/ml was
observed between the 24- and 48-h time points. Similarly, when
FIG. 1. In vitro dose-response curves for posaconazole against Fusarium solani clinical isolate 95-2478 at 1  104 conidia/ml (A and B) and 1  105
conidia/ml (C and D) after 24 h (A and C) and 48 h (B and D) of incubation. Curves were generated by fitting XTT absorbance data to a four-parameter
inhibitory sigmoid model. The concentrations resulting in 50% and 90% inhibition of growth (IC50 and IC90) and coefficients of determination (R
2) are
reported.
FIG. 2. Posaconazole bioassay standard curve (A) and serum concentrations (B) measured in uninfected and nonimmunosuppressed mice.
Blood was collected 4 h after the fifth dose in each regimen (posaconazole at 6.25, 12.5, 25, and 50 mg/kg by oral gavage BID) used in the treatment
and prophylactic studies. Candida kefyr ATCC 66028 served as the indicator organism for the bioassay, and zones of inhibition were measured after
48 h of incubation.
1056 WIEDERHOLD ET AL. ANTIMICROB. AGENTS CHEMOTHER.
the concentration-response curve was obtained using the XTT
colorimetric assay, a 2.75-fold increase in the posaconazole
IC50 value was also measured between the two incubation
periods, and the IC90 value was also increased (4.1 g/ml
versus 8 g/ml, respectively) (Fig. 1A and B). When the
starting inoculum was increased to 1  105 conidia/ml, the
potency of posaconazole against this isolate was markedly re-
duced at both 24 and 48 h as measured by elevated MICs (8
g/ml at both time points) and further increases in the calcu-
lated IC50 and IC90 values (Fig. 1C and D).
Serum concentrations. Posaconazole serum concentrations
were measured by bioassay at 4 h following the fifth dose in
uninfected and nonimmunosuppressed mice. This time point
was chosen as it has been reported that a posaconazole con-
centration of 0.7 g/ml drawn 3 to 5 h postdose is associated
with improved prophylactic efficacy (7). In addition, average
serum concentrations of 1.2 g/ml were associated with im-
proved efficacy when posaconazole was used as salvage therapy
for invasive aspergillosis (22). As shown in Fig. 2, the highest
posaconazole dosage group (50 mg/kg BID) achieved a median
posaconazole serum concentration of 5.3 g/ml (range, 4.9 to
6.2 g/ml), and decreasing concentrations were observed as
the dosages were lowered.
Treatment. In treatment studies an inoculum effect and a small
dose-response relationship were observed for posaconazole. In
the initial study, no improvement in survival (Fig. 3) or reduction
in tissue fungal burden within the kidneys (Table 1) was observed
following inoculation with 2.9  106 conidia/animal. Based on
these results this inoculum was used only once (n 10 animals
per group) and lower infecting inocula were evaluated for the
remainder of the study. In the mid-inoculum studies (6.5 105
to 6.8  105 conidia/animal), median survival increased in
animals that received BID posaconazole doses at 12.5 mg/kg
(7.5 days), 25 mg/kg (8 days), and 50 mg/kg (7 days) compared
to untreated controls (6 days; P  0.05), although the percent-
age of animals in these groups surviving to the end of the study
period was not improved (range, 0 to 5%). These results were
consistent with the modest reductions in kidney tissue fungal
burden within the 25- and 50-mg/kg dosage groups compared
to untreated controls (Table 1). No differences in tissue fungal
burden were observed in untreated controls that succumbed
early to infection (5 days postinoculation) compared to those
that survived longer (7 days).
When the infecting inocula were further lowered (7.7  104
to 7.8  104 conidia/animal), improvements in median survival
(15 days) and percent survival (64%) were observed for those
animals in the posaconazole 50-mg/kg BID dosage group com-
pared to untreated controls (8 days and 18%, respectively; P 
0.005). In addition, a significant reduction in kidney fungal
burden was also observed in mice that received this regimen.
However, it should also be noted that in the control group, the
median survival was increased and tissue fungal burden was
lower than in the corresponding untreated control group in the
mid-inoculum level. Although the median survival times in the
posaconazole 6.25-, 12.5-, and 25-mg/kg BID groups were
longer than those of untreated controls (12.5, 10, and 11 days,
respectively), these differences were not significant, nor were
the percentages of animals that survived to the end of the study
period (42, 25, and 38%, respectively). However, posaconazole
at 25 mg/kg BID did significantly reduce fungal burden within
the kidneys.
FIG. 3. Kaplan-Meier survival curves for the different posaconazole treatment dosage groups at the high inoculum (2.9  106 conidia/animal)
(A), mid-inoculum range (6.5  105 to 6.8  105 conidia/animal) (B), and low inoculum range (7.7  104 to 7.8  104 conidia/animal) (C).
Twice-daily dosing with oral posaconazole (black circles, 6.25 mg/kg; black triangles, 12.5 mg/kg; gray inverted triangles, 25 mg/kg; gray diamonds,
50 mg/kg) was initiated 12 h following intravenous inoculation in neutropenic mice, and values were compared to those for untreated controls
(black squares).
TABLE 1. Fusarium solani kidney tissue fungal burden in mice that received posaconazole as treatment beginning 12 h after inoculationa
Inoculum (no. of conidia/animal; no. of
animals/group)
Median log10 CFU/g in kidneys (range) for group:
Control
PSC at mg/kg:
6.25 12.5 25 50
High (2.9  106; 10) 5.8 (4.9–6.1) 5.6 (5.1–6.2) 5.3 (4.7–5.5) 5.3 (4.8–5.9) 5.2 (4.4–5.9)
Middle (6.5  105–6.8  105; 20) 6.1 (3.4–6.4) 6.0 (4.4–6.5) 5.8 (4.8–6.5) 5.6 (2.4–6.4)* 5.4 (3.7–6.4)*
Low (7.7  104–7.8  104; 20) 5.3 (3.1–6.3) 5.0 (2.7–5.9) 5.1 (1.2–6.2) 5.0 (1.5–5.9)* 4.6 (1.2–6.0)*
a Median log10 CFU/g values and ranges are reported for each dosage group. P values are reported for posaconazole (PSC) regimens with significant reductions in
log10 CFU/g compared to untreated controls (, P  0.05).
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Prophylaxis. Due to the poor overall survival among the
treatment groups and untreated controls at the highest inocu-
lum studied, only the mid- and low inoculum ranges were
evaluated in the prophylaxis studies. In the mid-inoculum study
(6.5  105 conidia/animal), the median survival (9 days) was
significantly improved in animals that received posaconazole at
50 mg/kg BID compared to untreated controls (7 days; P 
0.002; Fig. 4). In addition, tissue fungal burden was signifi-
cantly reduced within the kidneys at this dosage level com-
pared to untreated controls (Table 2). However, no improve-
ments in survival or reductions in tissue fungal burden were
observed with the other posaconazole regimens. As with the
treatment studies, no differences in tissue fungal burden were
observed between untreated controls that succumbed early to
infection and those that survived longer.
Similar to that observed in the treatment studies, an inocu-
lum effect was observed for survival in animals administered
posaconazole prophylaxis. As shown in Fig. 4, the median
survival in all prophylaxis groups and untreated controls at the
low inoculum was higher than that observed at the mid-inoc-
ulum. However, only animals that received posaconazole at 50
mg/kg BID had a median survival (15 days) that was signif-
icantly greater than that of untreated controls (10 days; P 
0.02), and only this dosage resulted in significant reductions in
tissue burden within the kidneys (Table 2).
DISCUSSION
Invasive infections caused by Fusarium species are difficult
to treat and are often associated with poor clinical outcomes.
The availability of advanced expanded-spectrum triazoles (i.e.,
voriconazole and posaconazole) has resulted in a modest im-
provement in treatment response. In a multicenter, open-label
study of voriconazole as salvage therapy, a satisfactory global
response was reported in 5 of 11 patients (45%) with fusariosis
(17). However, it is important to remember that in this study
stable disease was considered part of the global response. This
is in contrast to a recent report of 21 patients who received
posaconazole salvage therapy for proven or probable invasive
fusariosis (18). In this retrospective analysis of three indepen-
dent, multicenter open-label trials, which defined a successful
outcome as complete or partial response and classified those with
stable disease as failures, the overall response rate was 48%.
One potential reason for the poor response rates in clinical
studies of invasive fusariosis is the limited activity of antifungal
agents against Fusarium species (8, 10, 16). However, modifi-
cations to testing parameters used in determining the in vitro
activity can affect these results. Paphitou et al. noted that an
increased inoculum size and lengthened duration of incubation
resulted in higher azole MICs (16). Interestingly, one of the F.
solani isolates reported by these authors (24-h MIC, 2 g/ml)
was previously shown to be responsive in vivo to posaconazole
at 100 mg/kg despite minimal in vitro activity of this azole (48-h
MIC, 16 g/ml) (10, 16). A recent study also reported im-
proved survival in mice dosed with posaconazole at 100 mg/kg
following infection with a Fusarium oxysporum isolate with an
MIC of 16 g/ml (20).
The results of our study are consistent with these previous
reports. Survival was improved and tissue fungal burden within
FIG. 4. Kaplan-Meier survival curves for the different posaconazole prophylaxis dosage groups at the mid-inoculum (6.5  105 conidia/animal)
(A) and low inoculum (7.5  104 conidia/animal) (B). Twice-daily oral dosing with posaconazole (black circles, 6.25 mg/kg; black triangles, 12.5
mg/kg; gray inverted triangles, 25 mg/kg; gray diamonds, 50 mg/kg) was initiated 2 days prior to intravenous inoculation in neutropenic mice, and
values were compared to those for untreated controls (black squares).
TABLE 2. Fusarium solani kidney tissue fungal burden in mice that received posaconazole as prophylaxis beginning 2 days prior to
intravenous inoculationa
Inoculum
(no. of conidia/animal; no.
of animals/group)
Median log10 CFU/g of kidneys (range) for group:
Control
PSC at mg/kg:
6.25 12.5 25 50
Middle (6.5  105; 10) 5.8 (1.3–6.5) 5.6 (4.0–6.2) 5.5 (3.2–6.2) 5.5 (3.2–6.3) 4.7 (1.3–6.2)*
Low (7.5  104; 10) 4.4 (3.3–6.1) 2.8 (1.6–6.0) 4.4 (1.3–5.9) 4.5 (1.8–6.1) 2.9 (1.3–5.1)**
a Median log10 CFU/g values and ranges are reported for each dosage group. P values are reported for posaconazole (PSC) regimens with significant reductions in
log10 CFU/g compared to untreated controls (, P  0.02; , P  0.03).
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the kidneys was significantly reduced in mice that received
escalating dosages of posaconazole. This was consistently
found with the highest-dose regimen of posaconazole evalu-
ated (50 mg/kg BID). We also found discrepancies between the
in vitro activities of this azole when measured after 24 and 48 h
and observed that the survival and tissue burden results were
also related to the infecting inoculum sizes. This may be rele-
vant as the lowest inoculum size used in vitro was similar to the
lowest in vivo inoculum range where the greatest improve-
ments in survival and reductions in tissue burden were ob-
served. We also measured serum concentrations and found an
association between levels achieved 4 h after administration of
posaconazole and efficacy. Animals in the 50-mg/kg posacon-
azole BID group had the highest serum concentrations as well
as the greatest improvements in survival and reductions in
tissue burden. The median plasma concentration achieved in
this group (5.3 g/ml) was similar to the in vitro IC90 value
after 24 h of incubation at the lower starting inoculum (4.1
g/ml) but was less than that for the higher inoculum (7.2
g/ml). These data suggest that the in vivo efficacy was also
related to the starting inoculum, which is in agreement with the
results of Paphitou et al. (16), as well as clinical data demon-
strating improved outcomes with higher posaconazole concen-
trations (6, 7, 22).
Although our results are consistent with those reported by
others, several differences must be considered. The types of
immunosuppression used, if any, were different among the
studies, as were the species of Fusarium tested (F. oxysporum
and F. solani), and the inoculum sizes used to establish infec-
tion. In addition, we did not evaluate the efficacy of combina-
tion therapy, which was recently shown to be effective (20).
Finally, the serum concentrations measured at the highest-
dose posaconazole regimen used in our study are much higher
than can currently be achieved clinically (5–7, 21). A more
detailed analysis comparing a larger number of Fusarium iso-
lates along with a more rigorous pharmacokinetic/pharmaco-
dynamic analysis is needed to clarify the relationships between
in vitro potency, in vivo efficacy, and bloodstream concentra-
tions.
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